Our team
Scientists and builders, united by one mission.
Imagenomix brings together AI researchers, molecular pathologists, and oncologists to make genomic insight reachable for every cancer patient, on technology discovered at NYU Langone in 2017.
Leadership
The people behind IGX Predict™.
Chief Executive OfficerTravis Wold
Chief Executive Officer
Decades building oncology diagnostics companies and guiding them to IPOs and acquisitions. As Chief Commercial Officer at Circulogene he built the commercial organization from the ground up through to its acquisition; he was International Director at Veracyte through its IPO, and CEO of Kusko through its acquisition. He brings deep expertise in biopharma partnerships, clinical trial enrichment, and precision-medicine commercialization.
Chief Technology OfficerMikhail Teverovskiy, PhD
Chief Technology Officer
Dr. Teverovskiy specializes in AI for cancer diagnostics and medical imaging. An IEEE Senior Member, he is a recognized leader with extensive publications advancing AI in healthcare. He leads the development of the IGX Predict™ platform, directing algorithm development, model training, and technical infrastructure.
Principal AI Data ScientistLizabeth Katsnelson, PhD
Principal AI Data Scientist
Dr. Katsnelson is a computational biologist specializing in precision oncology. With expertise in machine learning and multimodal data integration, she leads efforts in the training, testing, and deployment of AI models for biomarker prediction within the IGX Predict™ product suite. She is dedicated to advancing cancer diagnostics and improving patient outcomes through innovative computational strategies.
Founders
Founded in the lab, for the clinic.
Imagenomix was founded by three physician-scientists at NYU Langone Health who saw that the answers oncologists need are already present in the slides they read every day.
Co-FounderAris Tsirigos, PhD
Co-Founder
A leader in computational biology at NYU Langone and an inventor on the patents behind the platform. His research pioneered histology-based forecasting of genetic alterations, the foundation IGX Predict™ is built on.
Co-FounderMatija Snuderl, MD
Co-Founder
Neuropathologist, Professor of Pathology, and Director of Molecular Pathology and Diagnostics at NYU Langone. He guides clinical and regulatory strategy and shapes the direction of NeuroInsight.
Co-FounderDaniel Orringer, MD
Co-Founder
Associate Professor of Neurosurgery at NYU Langone and a pioneer of AI in clinical medicine, known for advancing stimulated Raman histology to bring real-time intelligence into the operating room.
Science
Published and peer-reviewed.
The work behind the platform, in the literature and in preparation.
Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning
Coudray N, et al., with Aris Tsirigos. Nature Medicine, 2018. The landmark study that first established image-based mutation prediction.
BLISS: self-supervised prediction of breast cancer driver mutations from H&E whole-slide images
Katsnelson L, et al. Imagenomix and NYU Langone Health.
Image-based prediction of AKT1 and PIK3CA alterations in breast cancer for trial enrichment
Imagenomix, with clinical collaborators.
Computational pathology and genomic forecasting
Selected work from Aris Tsirigos, available on Google Scholar.
Molecular neuropathology and diagnostics
Selected work from Matija Snuderl, available on Google Scholar.
Help make this reachable for everyone.
We're growing our team across AI, molecular pathology, and commercial as we bring IGX Predict™ to more patients. If you want your work to reach people who would otherwise go untested, we'd like to talk.
Imagenomix Corp · New York, NY · Contact